Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Oświęcim – page 38

1 232 clinical trials in Oświęcim, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Oświęcim at a glance
1 232
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 232 trials in Oświęcim

Open in trial search

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:EXPD-101
  • Sponsor:Expedition Therapeutics Inc.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Colitis ulcerative

Not yet recruiting

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:ATH-063 hydrochloride
  • Sponsor:Athos Therapeutics Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ENV-294
  • Sponsor:Enveda Therapeutics Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Other cities in Poland

The busiest research cities in the country

All 235 cities in Poland

Clinical research in Oświęcim

What the registry says about research in the country

01 Neurology and Neurodegenerative Diseases

Clinical research in Oświęcim is strongly focused on neurology, with studies addressing migraine, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and multiple system atrophy. These trials are mainly testing new treatment options and exploring ways to slow disease progression, improve symptom control, and support daily functioning.

  • Acute and preventive approaches for migraine and chronic migraine
  • Treatments for Parkinson’s disease and multiple system atrophy
  • Therapies for multiple sclerosis and related spasticity
  • Research in Alzheimer’s disease and cognitive decline

The overall goal is to identify therapies that may better manage symptoms while also improving long-term neurological outcomes.

02 Cardiovascular and Metabolic Research

Another major area of activity covers cardiovascular diseases and metabolic disorders, including heart failure, arterial hypertension, atrial fibrillation, myocardial infarction, obesity, and type 2 diabetes. The studies are designed to evaluate treatment effectiveness, improve risk reduction, and support better control of blood pressure, heart function, and blood sugar.

  • Studies in heart failure and recovery after myocardial infarction
  • Blood pressure control in arterial hypertension
  • Stroke prevention in atrial fibrillation
  • Weight and glucose management in obesity and diabetes

These trials reflect a clear interest in preventing complications and improving long-term cardiovascular and metabolic health.

03 Gastroenterology and Inflammatory Bowel Disease

Research in digestive system diseases is active, especially for Crohn’s disease and ulcerative colitis. Trials in this area are evaluating new therapies that aim to reduce inflammation, help patients reach remission, and improve digestive symptoms and quality of life.

  • Crohn’s disease treatment studies
  • Ulcerative colitis research, including long-term control
  • Assessment of clinical and endoscopic response
  • Testing novel anti-inflammatory therapies

This field remains one of the most prominent therapeutic areas in the city’s trial landscape.

04 Respiratory and Lung Diseases

Several trials focus on respiratory tract diseases, including asthma, chronic obstructive pulmonary disease, respiratory tract infections, and inflammatory lung disease. The research is centered on testing therapies that may improve breathing, reduce inflammation, and better control flare-ups.

  • Asthma and COPD management
  • Inflammatory lung disease research
  • Studies of respiratory infection-related outcomes
  • Exploration of new anti-inflammatory approaches

These studies aim to support more effective symptom relief and stronger disease control.

05 Immunology, Dermatology, and Allergic Conditions

The city also hosts trials in immune system diseases, skin and connective tissue diseases, and allergic conditions. Key areas include psoriasis, chronic spontaneous urticaria, cold-induced urticaria, cutaneous lupus erythematosus, and other inflammatory skin disorders, with research aimed at improving symptom relief and treatment response.

  • Psoriasis and related inflammatory skin disease studies
  • Urticaria research for chronic itch and hives
  • Autoimmune skin condition investigations
  • Testing new immune-targeted therapies

These trials are important for patients whose symptoms remain difficult to control with standard care.

06 Musculoskeletal and Pain Research

Trials in musculoskeletal diseases and pain conditions include chronic low back pain, post-surgical neuropathic pain, post-herpetic neuralgia, and spasticity-related disorders. The main focus is to assess whether new therapies can reduce pain, ease stiffness, and improve movement and comfort in daily life.

  • Chronic non-specific low back pain studies
  • Neuropathic pain after surgery or herpes zoster
  • Spasticity research in upper-limb conditions
  • Evaluation of symptom relief and functional improvement

In Oświęcim, this area reflects ongoing efforts to improve quality of life for patients living with persistent pain and mobility limits.

07 Endocrinology, Nutrition, and Weight Management

Research related to hormonal diseases and nutritional and metabolic diseases includes type 1 diabetes, type 2 diabetes, obesity, overweight, and mixed dyslipidemia. These studies are largely aimed at improving metabolic control, supporting weight reduction, and lowering long-term health risks.

  • Blood sugar control in type 1 and type 2 diabetes
  • Weight management in obesity and overweight
  • Lipid disorder treatment research
  • Assessment of metabolic and cardiovascular benefit

This area shows a strong interest in therapies that address both disease control and broader cardiometabolic health.

08 Oncology

Within neoplasms, studies include breast cancer, non-small cell lung cancer, and metastatic hormone-sensitive prostate cancer. The trials are designed to test new treatment strategies, evaluate safety, and look for better ways to manage advanced or difficult-to-treat cancers.

  • Breast cancer research
  • Advanced lung cancer treatment studies
  • Prostate cancer investigations
  • Evaluation of novel cancer therapies

These oncology studies contribute to the search for more effective and tolerable cancer care.

09 Rheumatology and Autoimmune Disease

Some trials focus on broader immune-mediated inflammation and related autoimmune disorders such as Crohn’s disease, ulcerative colitis, and lupus-related conditions. The purpose is to explore treatments that may control immune activity more effectively and reduce disease burden over time.

  • Immune-mediated inflammation research
  • Autoimmune disease symptom control
  • Treatment studies for chronic inflammatory conditions
  • Evaluation of long-term disease management strategies

These studies are relevant for patients needing better options when standard therapies are not enough.

10 Gastroesophageal and Nutritional Recovery Research

Smaller but notable studies cover conditions such as erosive esophagitis, short bowel syndrome-associated intestinal failure, and post-surgical nutritional challenges. This work aims to improve digestive recovery, symptom relief, and overall nutritional status.

  • Upper digestive tract disease research
  • Intestinal failure after major bowel loss
  • Post-surgical digestive and nutritional support studies
  • Assessment of treatment benefit in complex digestive care

These trials address highly specific needs in patients with limited treatment options.

11 Psychiatry and Cognitive Health

There is also research in mental disorders and cognitive symptoms, including agitation in dementia and mild cognitive impairment. The studies are intended to evaluate therapies that may improve behavior, thinking, and overall functioning for patients and caregivers alike.

  • Agitation in Alzheimer’s-type dementia
  • Cognitive impairment and early dementia studies
  • Assessment of symptom relief and daily functioning
  • Development of better support for neuropsychiatric symptoms

These trials highlight the growing connection between brain health, behavior, and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.